The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
684
Eyedrops
Change from baseline (Day 1) to Week 2, Week 6, and Week 12 in IOP.
Change from baseline (Day 1) to Week 2, Week 6, and Week 12 in IOP at three time points (8:00 a.m.; 10:00 a.m.; 4:00 p.m.) in the study eye.
Time frame: up to Week12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arizona Eye Center - Chandler
Chandler, Arizona, United States
Eye Physicians & Surgeons of Arizona - Glendale Office
Glendale, Arizona, United States
Arizona Glaucoma Specialists - Phoenix
Phoenix, Arizona, United States
Walman Eye Center - Sun City
Sun City, Arizona, United States
Velvet Clinical Research
Burbank, California, United States
Specialty Eye Care Medical Center - Glendale
Glendale, California, United States
Global Research Management, Inc.
Glendale, California, United States
Inland Eye Specialists - Hemet
Hemet, California, United States
Diabetic Eye Medical Clinic - Inglewood
Inglewood, California, United States
Lakeside Vision Center - Irvine
Irvine, California, United States
...and 54 more locations